Enanta Pharmaceuticals, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging -18.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q3 FY26 | $-0.37 | $-0.67 | -81.1% | Miss | |
| Q2 FY26 | $-0.46 | $-0.45 | +2.2% | Beat | |
| Q1 FY26 | $-0.54 | $-0.42 | +22.2% | Beat |
Back to ENTA overview · ENTA holders · ENTA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.